IDEXX Laboratories, Inc. $IDXX Stock Position Decreased by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 55,153 shares of the company’s stock after selling 3,657 shares during the quarter. IDEXX Laboratories makes up approximately 1.1% of Beacon Investment Advisory Services Inc.’s holdings, making the stock its 29th biggest holding. Beacon Investment Advisory Services Inc.’s holdings in IDEXX Laboratories were worth $29,035,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SHP Wealth Management bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $26,000. Elevation Wealth Partners LLC boosted its position in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after purchasing an additional 32 shares during the period. Virtus Advisers LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth $26,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the 2nd quarter worth $30,000. Finally, Arlington Trust Co LLC increased its position in IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after buying an additional 19 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 0.6%

NASDAQ:IDXX opened at $586.67 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98. The stock has a market cap of $46.22 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 3.20 and a beta of 1.54. The business has a fifty day moving average of $559.73 and a 200-day moving average of $585.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion for the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the business earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. UBS Group boosted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Citigroup upped their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $756.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.